Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Table of study acronyms

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques: Injection, Inhibition

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Treatment groups in included trials

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques: Injection

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Summary of findings: bevacizumab versus ranibizumab

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Summary of findings: anti‐VEGF treatment versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.1 Gain of 15 or more letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.2 Gain of 15 or more letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 1 year: ranibizumab versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 2 years: ranibizumab versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 1 Gain of 15 or more letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.1 Gain of 15 or more letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 2 Gain of 15 or more letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.2 Gain of 15 or more letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 3 Loss of fewer than 15 letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 4 Loss of fewer than 15 letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 5 Visual acuity better than 20/200 at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 6 Visual acuity better than 20/200 at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 7 Mean change in visual acuity at 1 year (number of letters).

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 8 Mean change in visual acuity at 2 years (number of letters).

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 9 Reduction in central retinal thickness at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 10 Reduction in central retinal thickness at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 11 No problems in quality of life domain at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 12 No problems in quality of life domain at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 1 year: bevacizumab versus ranibizumab

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 2 years: bevacizumab versus ranibizumab

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 13 Loss of fewer than 30 letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Anti‐VEGF treatment versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: Cureus

Article Title: Antimicrobial Effectiveness Testing of Resorbable Electrospun Fiber Matrix per United States Pharmacopeia (USP) <51>

doi: 10.7759/cureus.50055

Figure Lengend Snippet: Results of USP <51> Antimicrobial Effectiveness Testing for micronized SEFM The limit of detection for this assay was 50 CFU/mL. Values observed below this limit are presented as <5.00E+01 in the table above. USP = United States Pharmacopeia; SEFM = synthetic electrospun fiber matrix; m-SEFM = micronized synthetic electrospun fiber matrix; CFU = colony forming units.

Article Snippet: The SEFM is a soft, white, conformable, nonfriable, absorbable material available in both sheet form (s-SEFM) and in micronized form (m-SEFM) (MiniMatrix®, Acera Surgical, Inc., St. Louis, Mo) [ ].

Techniques: